A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout.

Trial Profile

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Gout; Hyperuricaemia
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 16 Nov 2016 Results assessing frequency of acute flares presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
    • 13 Nov 2016 Results published in the Takeda Media Release.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top